Disease · MONDO_8000010
antiphospholipid syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. antiphospholipid syndrome. Diseases, record MONDO_8000010. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_8000010
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Antiphospholipid syndrome (disorder), Hughes syndrome, antiphospholipid antibody syndrome, familial lupus anticoagulant
- Open Targets
Drugs25
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PREDNISONE | CHEMBL635 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PROGESTERONE | CHEMBL103 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYDROXYCHLOROQUINE | CHEMBL1535 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TELITACICEPT | CHEMBL5095293 | Protein | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ANIFROLUMAB | CHEMBL2364653 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CERTOLIZUMAB PEGOL | CHEMBL1201831 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CROVALIMAB | CHEMBL4594316 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OLENDALIZUMAB | CHEMBL3990025 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SIROLIMUS | CHEMBL413 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ZANUBRUTINIB | CHEMBL3936761 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 25
See all 25 drugsTargets20
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PTGS2 | Cyclooxygenase | 4 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Unknown | https://conductscience.org/library/genes/5743 | Drugs and targets |
| C5 | Complement C5 | 2 | Complement C5 inhibitor | Phase 2 | https://conductscience.org/library/genes/727 | Drugs and targets |
| F10 | Coagulation factor X | 2 | Coagulation factor X inhibitor | Unknown | https://conductscience.org/library/genes/2159 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5742 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 1 | Tyrosine-protein kinase BTK inhibitor | Phase 2 | https://conductscience.org/library/genes/695 | Drugs and targets |
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | 1 | Lymphocyte differentiation antigen CD38 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/952 | Drugs and targets |
| CD52 | CAMPATH-1 antigen | 1 | CAMPATH-1 antigen inhibitor | Phase 1 | https://conductscience.org/library/genes/1043 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 1 | Granulocyte colony stimulating factor receptor agonist | Unknown | https://conductscience.org/library/genes/1441 | Drugs and targets |
| F2 | Prothrombin | 1 | Thrombin inhibitor | Unknown | https://conductscience.org/library/genes/2147 | Drugs and targets |
| FAAH | Fatty-acid amide hydrolase 1 | 1 | Anandamide amidohydrolase inhibitor | Unknown | https://conductscience.org/library/genes/2166 | Drugs and targets |
1 to 10 of 20
See all 20 targetsTrials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02128269 | Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome | Phase 2 | 9 | 2017-07-13 | Antiphospholipid (aPL)-Positive | OLENDALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04262492 | International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants | 500 | Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use | RIVAROXABAN | Its record names the disease | ClinicalTrials.gov | ||
| NCT06884384 | DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study | 310 | Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events | WARFARIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT04558268 | Low Dose Prednisone Therapy in Women With Recurrent Pregnancy Loss | Phase 2/3 | 242 | Recurrent Pregnancy Loss(RPL), Recurrent Miscarriage | PREDNISONE, PROGESTERONE | Its record names the disease | ClinicalTrials.gov | |
| NCT04918524 | The Clinical Features and Pregnancy Outcomes of CTD Patients | 126 | Connective Tissue Diseases, Pregnancy Related | ASPIRIN, ENOXAPARIN, HYDROXYCHLOROQUINE, PREDNISONE | Its record names the disease | ClinicalTrials.gov | ||
| NCT05644210 | Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE | 80 | Antiphospholipid Syndrome | RITUXIMAB, TELITACICEPT | Its record names the disease | ClinicalTrials.gov | ||
| NCT06504420 | The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study | Phase 2 | 70 | Primary Antiphospholipid Syndrome | SIROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT03152058 | IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy | Phase 2 | 55 | High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant Disorder | CERTOLIZUMAB PEGOL | Its record names the disease | ClinicalTrials.gov | |
| NCT02218476 | Beneficial Effects of Coenzyme Q10 Treatment on the Mitochondrial Dysfunction and Oxidative Stress Associated to Atherothrombosis Developement in Antiphospholipidid Syndrome Patients | Not applicable | 50 | Coenzyme Q10 on Athero-thrombosis in APS Patients | UBIDECARENONE | Its record names the disease | ClinicalTrials.gov | |
| NCT03180190 | Genetic Variants in Egyptian Patients Receiving HCQ(Hydroxychloroquine) | 50 | Autoimmune Diseases | HYDROXYCHLOROQUINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_8000010
GET https://conductscience.org/api/diseases/v1/MONDO_8000010/drugs?page=2